Sun Pharma Advanced Research Company Limited (NSE:SPARC)
India · Delayed Price · Currency is INR 196.37
-15.74 (-7.42%)
Jun 1, 2026, 3:30 PM IST
NSE:SPARC Revenue
In the fiscal year ending March 31, 2026, Sun Pharma Advanced Research Company had annual revenue of 391.50M INR, down -45.45%. Sun Pharma Advanced Research Company had revenue of 18.53B in the quarter ending March 31, 2026, with 6,716.82% growth.
Revenue
391.50M
Revenue Growth
-45.45%
P/S Ratio
175.82
Revenue / Employee
1.24M
Employees
316
Market Cap
68.83B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 391.50M | -326.16M | -45.45% |
| Mar 31, 2025 | 717.66M | -37.79M | -5.00% |
| Mar 31, 2024 | 755.45M | -1.63B | -68.36% |
| Mar 31, 2023 | 2.39B | 1.02B | 73.98% |
| Mar 31, 2022 | 1.37B | -1.16B | -45.74% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Alembic Pharmaceuticals | 73.45B |
| Strides Pharma Science | 48.59B |
| NATCO Pharma | 43.76B |
| Akums Drugs and Pharmaceuticals | 43.59B |
| Alivus Life Sciences | 25.52B |
| Cohance Lifesciences | 22.69B |
| Aarti Pharmalabs | 18.29B |
| Innova Captab | 16.30B |
Sun Pharma Advanced Research Company News
- 7 days ago - Sun Pharma Advanced Research Company receives Rs 149.99 crore for warrant allotment - Business Upturn
- 7 days ago - 52-week high stocks today: Apollo Micro up 8.69%, NRB Bearings gains 5.28%, Angel One rises 2.11%; HFCL, SPARC and Timex hit fresh highs - Business Upturn
- 13 days ago - Sun Pharma Advanced Research partner receives FDA response on PDP-716 application - Business Upturn
- 13 days ago - Why are Sun Pharma Advanced shares up over 14% today? Explained - Business Upturn
- 14 days ago - Sun Pharma Advanced Research Company Quarterly report: Q4 2026 - Filings
- 4 weeks ago - Sun Pharma Advanced Research Company sells priority review voucher for $195 million - Business Upturn
- 2 months ago - Why Sun Pharma shares are falling nearly 3% today? Epxlained - Business Upturn
- 4 months ago - Sun Pharma Advanced Research Company Quarterly report: Q3 2026 - Filings